Publicaciones en colaboración con investigadores/as de Hospital Regional Universitario de Málaga (17)

2024

  1. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 10, pp. 2648-2668.e2

2023

  1. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 11, pp. 2851-2874

  2. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

2022

  1. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 8, pp. 2313-2336

  2. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 8, pp. 2337-2354

2021

  1. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy

    Clinical and Translational Allergy, Vol. 11, Núm. 4

  2. COVID-19 pandemic and allergen immunotherapy—an EAACI survey

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 11, pp. 3504-3516

  3. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 648-676

  4. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 6, pp. 1629-1639

  5. Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 90-113

  6. Management of anaphylaxis due to COVID-19 vaccines in the elderly

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964

  7. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 6, pp. 1640-1660

2020

  1. Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019

    Allergy: European Journal of Allergy and Clinical Immunology

2019

  1. Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 3, pp. 432-448

  2. Prioritizing research challenges and funding for allergy and asthma and the need for translational research—The European Strategic Forum on Allergic Diseases

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 11, pp. 2064-2076

2014

  1. Act d 12 and Act d 13: Two novel, masked, relevant allergens in kiwifruit seeds

    Journal of Allergy and Clinical Immunology, Vol. 133, Núm. 6

  2. Detailed characterization of Act d 12 and Act d 13 from kiwi seeds: Implication in IgE cross-reactivity with peanut and tree nuts

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 69, Núm. 11, pp. 1481-1488